Gedatolisib + Talazoparib
Phase 1/2Active 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
TNBC - Triple-Negative Breast Cancer
Conditions
TNBC - Triple-Negative Breast Cancer
Trial Timeline
Apr 17, 2019 → Jul 1, 2024
NCT ID
NCT03911973About Gedatolisib + Talazoparib
Gedatolisib + Talazoparib is a phase 1/2 stage product being developed by Pfizer for TNBC - Triple-Negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03911973. Target conditions include TNBC - Triple-Negative Breast Cancer.
What happened to similar drugs?
0 of 2 similar drugs in TNBC - Triple-Negative Breast Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03911973 | Phase 1/2 | Active |
Competing Products
14 competing products in TNBC - Triple-Negative Breast Cancer